CTLA4 and hematologic disorder: Although CTLA-4 blockade has not been as extensively studied in hematologic malignancies, ipilimumab, an anti-CTLA-4 inhibitor approved for use in melanoma, was studied in a phase 1/1b study of patients with relapsed disease after allogeneic stem cell transplant [73].